Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Alta Partners

WebsiteLinkedInTwittercbCrunchbase
Status
ACTIVE
Global HQ
London, United Kingdom
Countries of investment
  • USA
Investment stages
  • Seed
  • Series A
Industries
  • Health Tech
  • Biotech
  • Digital Health
About
Alta Partners is a leading healthcare venture Capital firm founded in 1996 by senior partners from Burr, Egan, Deleage & Co. The firm has raised over $2 billion across 12 funds, focusing on life sciences and techenabled services companies. With a history of impactful investments, Alta Partners' portfolio has produced over 75 FDAapproved products and numerous successful mergers, acquisitions, and IPOs. The firm is dedicated to helping entrepreneurs build high impact companies and aims to integrate physicians, payers, and patients to deliver better outcomes, challenging the Traditional healthcare model. Alta Partners has offices in Jackson, WY, San Francisco Bay Area, and Denver.
Min check size
$500K
Max check size
$5M
Fund size
NPS

Investment Thesis

Alta Partners focuses on investing in life sciences and techenabled services companies, aiming to produce impactful results through trust, focus, and building strong relationships. They believe that Technology and innovation in healthcare can challenge the status quo and produce better outcomes for patients. Their investment strategy emphasizes building small, focused portfolios allowing for dedicated attention to each investment.
Lead investor
Co Invest
Number of exits
Preferred contact method

Alta Partners Contacts Information

Primary contact

Secondary contact

Portfolio

eGenesis

Tyra Biosciences

Variant Bio

Be Biopharma

Kelonia Therapeutics

Vir BioTech

DispatchHealth

Allakos

LJL BioSystems

ILEX Oncology

CoTherix

Aclara Biosciences

Definity Health

Eyetech Pharma

Angiosyn

Eyetech Pharmaceuticals

Agensys

Cellective Therapeutics

Kosan Bioscience

U3 Pharma

FoldRx Pharmaceuticals

Plexxikon

Cutera

Aegerion Pharmaceuticals

Astex Pharmaceuticals

Flamel Technologies

InterMune Pharmaceuticals

Swedish Orphan Biovitrum

Esperion Therapeutics

Applied Genetic Technologies Corp.

aTyr Pharma

Avid Radiopharmaceuticals

Calistoga Pharmaceuticals

Centrexion

ChemGenex Pharmaceuticals

Excaliard Pharmaceuticals

Immune Design Corp.

Kiadis Pharma

Kite Pharma

Lumena Pharmaceuticals

Neothetics

Prolacta Bioscience

Repros Therapeutics

SARcode Bioscience

Sutro Biopharma

Taligen Therapeutics

Trevena

Vertiflex

Zafgen

ZS Pharma

ACLARA Biosciences

Aerie Pharmaceuticals

Durata Therapeutics

Dynavax

Endonetics

Fate Therapeutics

Immunex

Mako Surgical

Orexigen Therapeutics

Relypsa

Tibia Therapeutics

Vical

Zancyte

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp